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Abstract		
	
Immunogenic	cell	death	is	a	recently	identified	subset	of	apoptotic	cell	death	that,	when	
activated,	may	improve	outcomes	and	remission	rates	in	cancer	patients.	Calreticulin	is	an	
essential	early-stage	damage-associated	molecular	pattern	that	is	triggered	by	certain	drugs.	It	
is	thought	that	cancer	chemotherapeutics	and	other	agents	proven	to	exhibit	immunogenic	cell	
death	do	so	by	creating	endoplasmic	reticulum	stress	that	causes	calreticulin	to	translocate	to	
the	cell	membrane	and	activate	more	downstream	signals	to	recruit	the	immune	system.	The	
current	gold	standard	for	the	detection	of	immunogenic	cell	death	is	a	lengthy	and	costly	
procedure	involving	immunocompetent	mice	vaccinated	with	cancer	cells	already	exposed	to	
the	potentially	immunogenic	agent.	This	is	not	a	realistic	method	to	screen	all	agents	for	their	
potential	to	induce	immunogenic	cell	death	(ICD),	but	the	only	other	pre-clinical	models	have	
been	done	in	only	one	cancer	cell	line.	This	study	aimed	to	generate	a	stable	murine	head	and	
neck	cancer	cell	line	to	be	used	for	screening	chemotherapeutics	using	fluorescence,	assess	the	
ability	of	these	transfected	cells	to	accurately	predict	ICD-inducing	potential,	and	test	newly	
modified	chemotherapeutics	for	their	potential	to	cause	ICD.	To	do	so,	cells	were	transfected	
with	a	plasmid	construct	for	the	calreticulin	protein	and	a	red-fluorescent	protein.	The	
fluorescent	model	is	not	a	replacement	for	the	gold-standard	detection	of	ICD,	but	rather	
enables	a	more	high-throughput	approach	to	the	widespread	testing	of	all	clinically	relevant	
cancer	chemotherapeutics	as	well	as	specifically	modified	chemotherapeutics	to	induce	ICD.		
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Chapter	1:	Introduction	
1.1 Summary	of	Cancer	Chemotherapy		
	 The	treatment	of	cancer	has	long	fascinated	scientists,	politicians,	and	humanitarians.		
Due	to	the	complex	nature	of	the	disease,	curative	chemotherapy	has	only	been	considered	a	
realistic	goal	for	a	few	decades.	In	fact,	chemotherapy	was	only	added	to	the	standard	of	care	
for	most	cancers	in	the	1960s.1	There	were	agents	available	prior	to	this	time	period,	such	as	
the	nitrogen	mustards	discovered	after	their	use	in	World	War	I,	but	the	agents’	intolerable	side	
effects	and	lack	of	specificity	for	cancer	cells	made	them	nearly	unusable.	The	rapid	resistance	
cancer	cells	developed	to	these	early	agents	was	a	problem	as	well.	Through	the	1940s,	surgery	
alone	was	the	standard	of	care,	and	in	the	1950s,	radiation	was	added.2	As	the	pathophysiology	
and	progression	of	the	disease	was	unraveled,	a	problem	with	the	surgery-only	approach	arose.	
With	the	understanding	of	metastasis--	when	cancer	cells	from	the	tumor	detach	from	the	main	
cell	and	establish	themselves	at	distant	sites	in	the	body--it	became	clear	that	surgery	alone	
would	not	be	enough	to	provide	a	cure	as	so	many	had	thought	before.		
	 By	the	1960s,	these	previously	toxic	agents	had	been	chemically	modified	and	new	
agents	were	discovered.	Some	toxicity	remained,	but	the	therapeutic	benefits	finally	
outweighed	the	risks.	It	was	clinically	beneficial	for	patients	to	receive	these	medications.	The	
idea	of	combination	chemotherapy,	using	multiple	drugs	with	multiple	mechanisms	of	action	at	
the	same	time,	was	tested	and	proved	to	work.		Chemotherapy	officially	became	part	of	the	
guidelines	and	standards	of	care	for	most	forms	of	cancer.	These	agents	provided	a	direct	effect	
onto	cancer	cells	themselves,	and	had	been	strongly	improved	since	the	literal	poisons	of	the	
early	century.	
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	As	more	and	more	researchers	began	to	study	cancer,	it	became	clear	that	the	disease	
differs	depending	on	the	originating	site	of	the	tumor.2	However,	discovery	of	these	disease	
markers	was	slow	until	the	targeted	therapy	revolution	of	the	1980s.1	With	specificity	in	mind	
and	an	ability	to	study	cancer	on	a	molecular	level,	it	was	possible	to	identify	markers	and	
molecular	targets	specifically	for	different	kinds	of	cancer.	Support	for	the	idea	of	a	single	
“magic	bullet”	to	destroy	all	forms	of	the	disease	rapidly	waned	as	it	was	shown	over	and	over	
again	to	be	an	unrealistic	goal.	Different	regimens	including	varied	mechanisms	of	
chemotherapy	combined	with	surgery	and	radiation	could	be	close	to	curative,	but	for	patients	
with	advanced	metastatic	disease,	the	treatment	remained	palliative.		
		 One	example	of	a	breakthrough	in	targeted	therapy	includes	the	checkpoint	inhibitors,	
useful	in	acute	or	chronic	myeloid	leukemia.	In	patients	with	a	Philadelphia	chromosome	
mutation,	this	type	of	leukemia	upregulates	a	specific	tyrosine	kinase	to	rapidly	grow	and	
differentiate.	Imatinib,	or	Gleevec,	is	used	to	inhibit	this	kinase	which	induces	apoptosis	in	
these	cancerous	cells.	This	has	showed	an	improvement	in	progression-free	survival	time	for	a	
significant	number	of	patients	as	compared	to	placebo.3	
	 Another	example	of	modern	targeted	therapy	is	immunotherapy	using	monoclonal	
antibodies.4This	concept	is	popular	in	many	chronic	disease	states	outside	of	cancer	including	
autoimmune	disorders,	and	has	dramatically	changed	the	prognosis	of	patients	with	HER2-
positive	breast	cancer.	Before	the	advent	of	trastuzumab5,6,	or	Herceptin,	HER2-positive	cancer	
was	considered	to	be	one	of	the	deadliest	forms	of	breast	cancer.	Due	to	the	rapid	proliferation	
and	metastasis	of	this	particular	breast	cancer,	it	was	often	resistant	to	treatment	or	detected	
too	late.	By	identifying	human	epidermal	growth	factor	receptor	2	as	an	overexpressed	target	
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on	these	cancer	cells,	the	development	of	an	antibody	to	bind	to	its	extracellular	domain	
resulted	in	nearly	curative	outcomes	in	a	previously	aggressive	disease.	When	used	as	an	
adjuvant	to	other	chemotherapy,	trastuzumab	mediates	antibody-dependent	cellular	
cytotoxicity	and	improves	overall	outcomes	including	increased	number	of	quality	of	life	years	
and	remission	rates.	
It	wasn’t	until	the	late	1980s	and	early	1990s	that	the	concept	of	a	cancer	vaccine	
arose.1,7Patients	who	had	been	successfully	treated	with	chemotherapy	years	prior	were	living	
long	enough	that	years	after	achieving	remission—clinically	undetectable	cancer—the	disease	
was	coming	back	and	it	was	much	more	difficult	to	treat.	Combination	chemotherapy	to	
combat	resistance	worked	for	the	initial	case,	but	wasn’t	always	a	permanent	solution	for	
metastatic	cancer.	The	idea	of	permanently	sensitizing	the	immune	system	to	a	specific	type	of	
cell,	as	with	infectious	diseases,	was	there	but	remained	undeveloped.	Vaccination	invokes	the	
necessary	aspect	of	immune	system	involvement8.	However,	the	very	nature	of	cancer	requires	
evasion	of	the	immune	system	to	continue	uncontrolled	proliferation.	In	addition	to	this,	many	
cancer	chemotherapeutics	cause	bone	marrow	suppression	and	as	a	result,	a	weakened	
immune	system.	The	concept	of	true	vaccination	in	cancer	is	challenging,	as	vaccination	would	
require	activation	of	the	already	debilitated	immune	system	by	a	stimulus	that	had	previously	
been	overlooked.	
Ideally,	it	would	be	possible	to	stimulate	even	a	weakened	immune	system	and	teach	it	
to	recognize	a	specific	type	of	cancer	via	cancer-specific	antigens.	As	the	idea	for	a	cancer	
vaccine	developed	and	later	shown	to	be	effective	and	clinically	relevant9,	there	was	more	work	
being	done	on	the	role	of	the	immune	system	in	patients	with	cancer.	It	had	been	discovered	
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that	anthracyclines	were	causing	an	unanticipated	and	previously	unnoticed	immune	
response.10	This	discovery	demanded	the	observation	that	cell	death	was	not	as	simple	as	
previously	presumed.	
According	to	the	old	school	of	thought,	there	were	only	two	kinds	of	cell	death:	
apoptosis	and	necrosis.11,12Apoptosis	happens	thousands,	even	millions	of	times	per	day	in	the	
human	body	as	the	natural	end	to	cells.	These	cells	have	divided	so	many	times	the	risk	of	
mutation	is	too	high	
for	the	cell	to	safely	
continue	dividing.	
This	mechanism	is	
one	of	the	body’s	
simplest	and	
endogenous	defenses	
against	formation	of	
cancerous	cells.	
Because	it	happens	so	
frequently	and	does	not	
typically	involve	the	immune	system	in	patients,	it	was	considered	“tolerogenic”	or	allowable	by	
the	immune	system,	excluding	patients	with	autoimmune	disease.	13,14On	the	other	hand,	
necrosis	is	cell	death	as	the	direct	result	of	a	pathogen	or	some	other	stimulus	killing	cells	prior	
to	their	planned	end.	It	was	thought	that	these	two	categories	of	cell	death	were	entirely	
Figure	1.	One	of	the	earliest	illustrations	suggesting	that	both	necrosis	and	
apoptosis	could	be	immunogenic.	Melcher	et.	al		Apoptosis	or	necrosis	for	
tumor	immunotherapy:	what’s	in	a	name?	J	Mol	Med	1999	77:824-83	
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discrete,	until	Casares	et.	al10	showed	that	specifically	anthracyclines	stimulate	the	immune	
system	to	later	recognize	the	types	of	tumors	that	have	been	proliferating.			
	
1.2 Immunogenic	Cell	Death		
The	idea	of	immunogenic	cell	death	as	a	specific	form	of	apoptosis	has	since	been	studied	
extensively,	but	ultimately	there	is	still	largely	conjecture	as	to	why	it	may	happen.	It	is	entirely	
possible	and	highly	likely	that	many	pathways	that	result	in	this	form	of	apoptosis	have	not	yet	
been	discovered.	Not	every	anticancer	agent	is	able	to	stimulate	this	response.	Interestingly	
enough,	agents	even	within	the	same	class	of	chemotherapeutic	drugs	differ	in	their	abilities	to	
induce	this	type	of	response	both	in	vitro	and	in	vivo.		
	
Bona	fide*	ICD-
inducing	drug	
Confirmed**	DAMPs	activated	
Bleomycin	 CALR,	ATP,	Type	I	IFN,	HMGB1	
Bortezomib	 CALR,	Type	I	IFN,	HMGB1	
Cyclophosphamide	 CALR,	ATP,	Type	I	IFN,	HMGB1	
Digoxin	 CALR,	ATP	
Doxorubicin	 CALR,	ATP,	Type	I	IFN,	HMGB1	
Epirubicin	 CALR,	ATP,	HMGB1	
Idarubicin	 CALR,	HMGB1	
Mafosfamide	 CALR,	HMGB1	
Mitoxantrone	 CALR,	ATP,	Type	I	IFN,	HMGB1	
Oxaliplatin	 CALR,	ATP,	Type	I	IFN	
Patupilone	 CALR,	Type	I	IFN,	HMGB1	
*bona	fide	as	tested	by	gold-standard	ICD	murine	vaccination	assay	
**	confirmed	as	tested—missing	DAMPs	from	each	box	have	yet	to	be	determined.	
CALR	=	calreticulin,	ATP	=	adenosine	triphosphate,	IFN	=	interferon,	HMGB1	=	high	mobility	
group	box	1,	DAMP	=	damage-associated	molecular	patterns	
Table	1.	A	list	of	confirmed	agents	that	induce	ICD	as	challenged	in	mice	and	their	confirmed	DAMPs.	
Adapted	from	Bezu	et.	al	Combinatorial	strategies	for	the	induction	of	immunogenic	cell	death.	Front.	
Immunol	6:187	2015	
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Immunogenic	cell	death	is	completely	dependent	on	the	establishment	of	a	stress	
response.15,16	That	stress	response	must	specifically	activate	certain	signals	that	alert	the	
adaptive	immune	system	via	dendritic	cells.	There	is	an	increasing	amount	of	clinical	data	that	
shows	engaging	the	immune	system	remains	clinically	relevant	even	when	the	patient	has	been	
in	stable	remission.17–19The	next	step	to	maintaining	curative	chemotherapy	and	an	alternative	
to	the	traditional	idea	of	a	cancer	vaccine	could	be	controlled	activation	of	this	type	of	cell	
death.	
	 The	key	to	inducing	immunogenic	cell	death	lies	with	a	protein	that	is	present	in	nearly	
every	mammalian	cell	and	does	not	under	normal	circumstances	influence	the	immune	
system.20This	protein,	calreticulin,	is	usually	found	in	the	endoplasmic	reticulum	and	is	involved	
in	the	regulation	of	
intracellular	calcium	release.	
However,	in	times	of	severe	
stress	on	the	cell,	it	is	able	to	
act	as	an	alarm	and	is	
translocated	to	the	cell	
membrane	where	it	affects	
the	downstream	release	and	
secretion	of	other	damage-
associated	molecular	patterns	
(DAMPs)	such	as	adenosine	
tri-phosphate	(ATP)	and	high-mobility	group	box	1	(HMGB1)	to	amplify	the	stress	response.		
Figure	2.	Schematic	of	immunogenic	cell	death.	Calreticulin	is	
translocated	to	the	cell	membrane,	docks	and	activates	other	damage-
molecular	patterns.	A.M.	Dudek	et.	al	Cytokine	&	Growth	Factor	
Reviews	24	(2013)	319-333	
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HMGB1	in	particular	works	on	toll-like	receptor	4	(TLR-4)21.	TLR-4	is	essential	for	an	
amplified	immune	response	to	these	cells	as	it	assists	in	the	processing	and	cross-presentation	
of	cancer	cells	to	dendritic	cells.	Dendritic	cells	are	essential	components	of	the	adaptive	
immune	system	response.22	Without	the	amplification	from	TLR-4	activation,	relapse	of	cancer	
has	been	shown	in	patients	to	be	not	only	more	frequent,	but	rapidly	occurring.	This	immune	
response	is	what	mediates	suppression	of	tumor	growth	as	well	as	determines	long-term	
survival	and	maintenance	of	remission	in	animal	models	as	well	as	patients.		
	 	As	shown	by	anthracyclines,	there	are	four	currently	identified	DAMPs14	required	for	
the	activation	of	the	immune	response.	It	is	likely	that	there	are	more	proteins	that	influence	
this	pathway,	but	these	four	are	essential	to	the	anthracycline	response.	It	is	also	possible	that	
other	drug	classes	may	require	more	or	different	proteins	to	exhibit	an	immune	response.	
However,	it	seems	these	four	are	a	minimum	requirement	for	the	induction	of	immunogenic	
cell	death,	and	stimulation	of	these	four	in	particular	to	create	an	immune	response	has	been	
seen	in	other	drug	classes	as	well.		
	The	first	required	step	is	the	extracellular	exposure	of	calreticulin.	This	leads	to	secretion	of	
ATP23	to	stimulate	the	recruitment	of	antigen-presenting	cells,	production	of	type	I	interferon,	
and	the	release	of	HMGB1	to	activate	TLR-4.	By	recruiting	antigen-presenting	cells,	these	
DAMPs	stimulate	uptake	processing	and	presentation	of	the	antigens	from	the	apoptotic	cells	
to	prime	the	adaptive	immune	response.	If	one	of	these	four	are	not	activated,	it	completely	
compromises	the	immunogenicity	and	does	not	result	in	ICD.	
Since	its	discovery,	many	investigations	into	the	mechanism	of	immunogenic	cell	death	have	
occurred.24–44A	large	percentage	of	these	studies	focus	specifically	on	calreticulin	as	the	earliest	
	 8	
and	one	of	the	most	important	molecular	targets	for	inducing	immunogenic	cell	death.	45–
53These	studies	have	shown	that	across	all	drug	classes	tested	thus	far,	inability	to	stimulate	
translocation	of	calreticulin	to	the	cell	membrane	equates	to	an	inability	to	induce	
immunogenic	cell	death.	It	is	suggested	that	endoplasmic	reticulum	stress	is	the	cause	of	
calreticulin	translocation54.	Cancer	chemotherapeutic	agents	are	not	the	only	methods	of	
inducing	ICD,	but	they	are	some	of	the	most	convenient.	Other	methods	include	radiation	and	
photodynamic	therapy,	and	ICD	is	also	shown	in	cells	treated	with	cardiac	glycosides.55,56,57	
	
While	it	is	now	possible	
to	provide	an	explanation	
of	how	it	happens,	there	is	
still	no	rapid	method	to	
indicate	the	possibility	of	a	
drug	inducing	
immunogenic	cell	death,	
and	there	have	been	no	
specific	drugs	synthesized	
for	the	purpose	of	inducing	
immunogenic	cell	death.	
These	investigations	have	
led	to	a	strong	foundation	that	illustrates	the	physiology	of	immunogenic	cell	death	at	a	cellular	
level,	but	the	possibility	remains	largely	untapped.58–62	In	addition,	the	high	cost	of	exploring	
Figure	3.	Illustration	of	molecular	mechanisms	of	DAMPs	in	ICD.	Krysko	et.	
al	Immunogenic	cell	death	and	DAMPs	in	cancer	therapy.	Nat	Rev	Cancer	
12:860-875	2012	
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the	immune	response	in	this	manner	has	prevented	the	investigation	of	ICD	in	all	
chemotherapeutic	products	used	in	regimens	today.	Creating	ICD	is	a	new	standard	that	
chemotherapy	regimens	must	be	held	to	in	order	to	maintain	remission	in	patients.	To	make	
this	feasible,	modification	of	current	agents	available	on	the	market	is	essential.48,49	It	is	also	
necessary	to	be	able	to	detect	ICD	potential	in	all	cancer	chemotherapeutic	agents	in	
widespread	clinical	use.	
	 The	current	gold	
standard	for	the	detection	of	
immunogenic	cell	death63	is	
not	easily	amenable	to	
testing	multiple	drugs	or	
concentrations.	It	is	an	
expensive,	slow	process	
requiring	immunocompetent	
murine	models	for	
vaccination	assays.	In	these	
assays,	tumor	cells	are	
exposed	in-vitro	to	a	
chemotherapeutic	agent	or	
another	stimulus	that	is	
purported	to	cause	an	immune	response.	The	cells	are	washed	and	re-suspended	in	PBS,	then	
injected	into	the	flank	of	a	mouse.	Since	the	result	is	dependent	on	a	functioning	immune	
Figure	4.	Illustration	of	the	gold	standard	procedure	for	detection	of	
ICD.	Kroemer	et.	al	Immunogenic	cell	death	in	cancer	therapy.	Ann	Rev	
Immunol	2013	31:51-72	
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system,	the	in-vitro	exposure	must	occur	in	a	murine	cell	line,	as	human	cells	will	not	grow	
tumors	in	immunocompetent	mice.	One	week	after	injection,	the	same	tumor	cells	are	injected	
into	the	opposite	flank	and	the	mice	are	monitored	for	tumor	growth.	When	the	cells	are	
exposed	to	doxorubicin,	a	typical	inducer	of	immunogenic	cell	death,	prior	to	injection,	80%	of	
mice	do	not	develop	tumors.		This	“gold	standard”	is	not	easily	affordable	to	the	discovery	of	
other	immunogenic	chemotherapeutics	due	to	the	cost	and	time	commitment.	Since	the	cells	
are	murine	cells	in	a	murine	model,	there	is	still	no	guarantee	that	the	response,	if	any,	will	
relate	to	a	similar	response	in	a	human	model.	
	
1.3 Platinum	chemotherapy	
	Platinum	compounds	are	used	in	over	half	of	all	patients	receiving	chemotherapy	
treatment.64	These	drugs	work	by	chelating	single-stranded	DNA	during	cell	division,	causing	a	
kink	that	stimulates	programmed	cell	death.65	Compared	to	more	modern	agents,	these	drugs	
are	not	particularly	cancer	specific.	Their	only	specificity	originates	from	the	idea	that	in	many	
cancers,	the	rate	of	cell	division	is	increased.	
Platinums	work	only	in	actively	dividing	cells	to	stop	
those	cells	from	further	dividing.	The	overall	
mechanism	of	action	remains	relatively	the	same	
across	every	drug	in	the	class,	but	there	is	only	one	
agent	that	causes	immunogenic	cell	death.		
	Cisplatin	is	the	oldest	of	these	compounds66	and	is	still	used	in	some	regimens	today	as	
it	has	been	studied	extensively	and	is	an	effective	agent	for	direct	killing.67–69It	is	a	relatively	
Figure	5:	Structure	of	Cisplatin	
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simple	molecular	structure	with	two	chlorides	to	act	as	the	leaving	groups,	leaving	the	central	
platinum	open	to	chelation	with	nucleic	acids.	However,	it	has	never	been	a	curative	treatment	
for	chemotherapy	due	to	the	problems	with	resistance	and	side	effects.	The	cisplatin	
resistance70,71	has	been	studied	extensively.		Resistance	caused	by	failure	to	achieve	a	drug	
concentration	high	enough	to	effectively	kill	cancer	cells	can	be	attributed	to	be	decreased	
uptake	of	the	drug	rather	than	increased	efflux	of	the	drug	by	cancer	cells.	The	dose	limiting	
toxicity	of	cisplatin	is	nephrotoxicity,	though	there	is	a	significant	amount	of	bone	marrow	
suppression	that	occurs	as	well	as	ototoxicity.		
As	an	effort	to	reduce	resistance	and	reduce	side	effects,	other	platinums	were	
developed.65,72The	first	of	these	was	carboplatin,	
modified	by	adding	a	dicarboxylate	in	place	of	the	
chloride	leaving	groups.	By	changing	the	central	
conformation,	it	showed	an	improved	toxicity	profile	
but	did	not	confer	an	improvement	to	resistance.	In	
fact,	the	level	of	cross-resistance	was	so	high	that	
eventually	carboplatin	fell	out	of	favor,	as	other	drugs	with	differing	mechanisms	of	action	
allowed	for	a	reduction	in	dose	of	cisplatin	in	combination	therapy	to	improve	the	incidence	of	
adverse	events.		
A	later	version,	oxaliplatin,	was	modified52	to	include	two	larger	donating	groups,	
changing	the	central	platinum	conformation	to	square	planar.	Due	to	its	chemical	structure,	
oxaliplatin	has	a	slightly	different	mechanism	of	action	and	a	different	dose-limiting	toxicity—
neurotoxicity.73,74Though	they	are	in	the	same	class	and	have	generally	the	same	mechanism	of	
Figure	6:	Structure	of	Carboplatin	
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action,	oxaliplatin	does	not	exhibit	cross-resistance	to	cisplatin,	does	not	have	the	same	dose-
limiting	toxicity,	and	is	used	in	different	cancer	chemotherapy	regimens.	Additionally,	
oxaliplatin	tends	to	exhibit	fewer	DNA	adducts	to	achieve	the	same	amount	of	growth	
inhibition,	which	is	typically	associated	with	crosslinked	protein	in	the	cytosol.	Cisplatin	is	not	
effective	in	colon	cancers,	but	oxaliplatin	is	first	line	for	colon	cancer	in	varying	concentrations,	
and	has	also	been	approved	for	pancreatic	cancer.75,76	
However,	their	use	in	current	regimens	is	not	the	only	difference	between	the	two	most	
common	platinums.	After	the	discovery	of	doxorubicin	to	induce	endogenous	immunogenic	
responses,	many	other	drugs	were	studied	for	this	same	response.14	It	was	discovered	that	
oxaliplatin	alone	of	the	platinums	also	had	the	ability	to	induce	immunogenic	cell	death.	This	is	
often	attributed	to	the	fact	that	oxaliplatin	causes	endoplasmic	reticulum	stress.	Cisplatin	does	
not	display	immunogenic	cell	death	unless	this	type	of	stress	is	exogenously	added	to	the	
treatment	regimen77,	in	which	case	the	immune	response	is	restored.	Thus,	it	is	likely	that	
cisplatin	does	not	cause	endoplasmic	reticulum	stress.	These	studies	further	proved	that	
calreticulin	motivated	by	endoplasmic	reticulum	stress	is	one	of	the	earliest	pathways	required	
to	induce	immunogenic	cell	death.34,50,78–84	
	
Figure	7:	Structure	of	Oxaliplatin	
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1.4 Niclosamide	
Niclosamide	is	primarily	classified	as	an	anti-helminthic	drug	used	to	treat	infectious	agents	
such	as	tapeworms.	It	is	given	orally	and	has	no	major	adverse	events	such	as	
immunosuppression,	neuropathy,	or	major	organ	toxicities85.	By	inhibiting	glucose	uptake,	it	
stops	oxidative	phosphorylation	and	anaerobic	metabolism.	Recent	investigations	into	the	drug	
show	beneficial	properties	as	an	adjuvant	agent	in	regimens	for	cancer	chemotherapies	as	an	
inhibitor	of	the	STAT3	pathway86.	Though	it	is	not	yet	considered	for	routine	clinical	use	and	is	
not	available	in	the	U.S.	due	to	lack	of	use,	many	early	or	pre-clinical	studies	show	its	efficacy	in	
a	wide	variety	of	cancers	including	but	not	limited	to	prostate,	renal,	ovarian,	oral,	colon,	lung,	
breast,	osteosarcomas	and	leukemias.	There	is	also	some	evidence	that	it	may	have	activity	
against	methicillin-resistant	staphylococcus	aureus87,	and	may	also	inhibit	early	stages	of	Zika	
replication.	Niclosamide	has	the	potential	to	positively	impact	cancer	chemotherapy	when	
added	to	older	chemotherapeutic	agents.88	Additionally,	it	is	an	old	drug	discovered	in	1958	
that	is	affordable	and	adds	no	risk	of	major	adverse	events	to	already	hazardous	chemotherapy	
regimens.		
	
Figure	8:	Structure	of	Niclosamide	
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1.5 Purpose		
	In	this	project,	we	aimed	to	(1)	adapt	a	pre-clinical	model	of	immunogenic	cell	death	to	
a	new	cell	line	using	fluorescent	tags,	(2)	characterize	expression	of	immunogenic	cell	death	in	
these	lines	using	known	ICD	inducers,	(3)	assess	the	capacity	of	modified	cytotoxic	
chemotherapeutics	to	induce	ICD	using	this	cell	line	as	a	pre-clinical	model.	The	gold-standard	
model	of	immunogenic	cell	death	was	first	illustrated	in	one	of	the	earliest	papers	on	the	ICD-
inducing	properties	of	doxorubicin,	an	anthracycline.	Providing	an	updated	model	in	a	new	cell	
line	has	many	benefits.	It	is	cheaper,	as	there	is	no	initial	work	using	costly	animals	or	
employees	trained	in	animal	care.	It	is	rapid,	as	potential	ICD	can	be	detected	in	under	three	
days.	With	an	updated	pre-clinical	model,	screening	agents	for	ICD	becomes	more	high-
throughput	and	more	realistic	to	do	on	a	larger	scale.			
	
Chapter	2:	Materials	and	Methods	
2.1 Summary	
This	project	aimed	to	establish	a	rapid	ICD	detection	method	adapted	from	Golden	et.	al56	in	a	
new	stable	murine	cell	line	expressing	calreticulin	and	a	fluorescent	marker	as	well	as	test	novel	
compounds	to	assess	ICD	potential.	To	do	so,	a	plasmid	construct	was	ordered	from	DNA	2.0	
(Now	ATUM)	that	encoded	for	calreticulin	and	resistance	genes.	After	purifying	the	plasmid	
DNA,	it	could	be	used	with	lipofectamine	transfection	in	several	cell	lines.	After	transfection,	
the	cells	containing	plasmid	expressing	the	calreticulin	protein	would	emit	fluorescence	in	the	
red	fluorescent	protein	range,	with	an	excitation	of	554	nm	and	emission	of	590	nm.	The	
fluorescence	would	be	displayed	intracellularly,	particularly	near	the	nucleus	as	the	protein	is	
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normally	displayed	on	the	endoplasmic	reticulum.	For	ease	of	imaging,	cell	nuclei	would	be	
stained	with	Hoechst	dye89,90,		excitation	of	361	nm	and	emission	of	497	nm.	After	selection	
with	antibiotics,	all	cells	should	contain	plasmid	and	would	fluoresce.	The	test	drugs	could	then	
be	applied.	After	short	incubation	with	the	drugs,	it	would	be	possible	to	tell	if	that	drug	caused	
Figure	9:	Phase	1	of	the	experimental	process	
	
Figure	10:	Phase	2	of	the	experimental	process.		
A.	Transient	transfection	process.	B.	stable	cell	line	process	
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sufficient	endoplasmic	reticulum	stress	to	induce	immunogenic	cell	death.	If	the	drug	did	cause	
immunogenic	cell	death,	the	calreticulin	construct	should	move	to	the	cell	membrane	where	it	
would	be	displayed	extracellularly.	Rather	than	relying	on	visual	red	fluorescence	alone,	a	
secondary	antibody	of	cell-impermeable	HaloTag	was	used.	This	HaloTag	would	be	able	to	bind	
and	fluoresce	to	only	external	calreticulin,	displaying	at	an	excitation	of	494	nm	and	an	
emission	of	517	nm.		
	
2.2 Isolation	and	purification	of	plasmid	DNA	
The	plasmid	obtained	from	DNA	2.0	contained	a	calreticulin	construct,	a	red	fluorescent	
protein,	a	G418	resistance	gene	for	selection	in	cell	culture,	and	an	ampicillin	resistance	gene	
for	selection	in	bacterial	culture.	Initially,	small	quantities	of	the	plasmid	were	generated	using	
the	bacterial	stab	given	by	DNA	2.0	and	the	PerfectPrep	mini	prep	kit	by	5	Prime.	Bacteria		
Figure	11:	Plasmid	map	(Adapted	from	DNA	2.0)	
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containing	the	plasmid	construct	were	grown	up	overnight	in	LB	media	containing	ampicillin	
and	purification	proceeded	as	directed	by	the	manual.		As	transfection	protocols	changed,	
larger	amounts	of	DNA	were	required	to	fit	demand.	A	maxi	prep	kit--PureLink	by	Invitrogen—	
became	essential.	However,	the	first	few	attempts	at	generating	a	suitable	concentration	of		
DNA	from	the	maxi	prep	kit	yielded	surprisingly	low	amounts	of	DNA.	Due	to	this	particular	
plasmid	being	a	low	copy	plasmid,	despite	the	mutated	origin	sequence,	overnight	incubation	
periods	were	extended	to	12-14	hours	at	minimum,	a	range	exceeding	the	upper	limit	
recommended	by	the	manufacturer.	To	further	improve	the	yield,	the	pellet	was	spun	down	at	
higher	speeds	and	in	a	centrifuge	equipped	specifically	for	large	volumes	of	bacterial	media	as	
opposed	losing	purified	DNA	and	bacteria	at	each	step	when	using	the	same	volume	split	
among	many	tubes	for	a	small	centrifuge.	The	final	step	to	improve	the	yield	was	using	double	
the	amount	of	bacterial	culture	media	recommended	by	the	manufacturer	for	low-copy	
plasmids.		
	
2.3 Transfection	
a. General	procedure	
Lipofectamine	is	a	lipophilic	agent	used	for	plasmid	transfection	into	cell	culture	that	
works	by	encapsulating	and	then	transporting	cationic	nucleic	acids	across	the	lipophilic	cell	
membrane.	The	lipofectamine	used	in	this	experiment	was	Lipofectamine	2000	(Invitrogen).	
The	general	procedure	takes	at	least	one	day	to	prepare,	one	day	to	transfect,	and	another	to	
select.	Cells	must	be	grown	up	overnight	on	a	6	well	plate.	The	formation	of	the	transfection	
complex	is	fairly	straightforward.	The	procedure	involves	incubating	at	room	temperature	a	
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calculated	amount	of	lipofectamine	and	a	calculated	amount	of	DNA	separately	for	5	minutes,	
each	in	150	microliters	of	serum-free	media.	After	the	incubation	period	is	up,	the	media	
containing	lipofectamine	and	DNA	is	mixed	together	and	incubated	at	room	temperature	for	20	
minutes.	After	20	minutes,	the	mixture	is	added	to	the	50-70%	confluent	cell	culture	and	
incubated	overnight.	In	the	morning,	cells	must	be	split.	24	hours	later,	the	cells	can	begin	
selection	with	G418	at	a	concentration	specific	to	each	cell	line.		
	
To	optimize	transfection,	several	variables	were	taken	into	account.	The	variables	
changed	were	the	ratio	of	lipofectamine	to	DNA,	with	or	without	fetal	bovine	serum,	
confluency	of	the	cells,	and	the	length	of	time	the	transfection	media	was	applied	to	the	cells.	
To	test	if	the	transfection	was	successful,	fluorescent	imaging	was	performed.		
	
	
Figure	12:	Sample	transfection	protocol	(doses	optimized	for	AT84	cells)	
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b. MDA	1986	cell	line	
MDA	1986	is	a	human	head	and	neck	cancer	cell	line.	It	was	cultured	in	DMEM	with	10%	
fetal	bovine	serum	or	10%	synthetic	serum,	Fetalgro	(RMBI).	The	cell	line	was	not	cultured	in	
antibiotics	as	typical	antibiotics,	such	as	penicillin/streptomycin,	used	in	cell	culture	may	
interact	with	the	uptake	of	G418	and	prevent	effective	selection.	The	initial	experiments	used	
complete	culture	media,	incubated	cells	overnight	in	transfection	media,	and	using	a	ratio	of	
Lipofectamine:	DNA	of	1:1	as	taken	from	the	manufacturer’s	instructions.	This	procedure	was	
modified	throughout	the	optimization	process	and	included	removing	fetal	bovine	serum	
during	transfection,	reducing	the	amount	of	incubation	with	transfection	media	to	4-6	hours,	
and	testing	various	ratios	of	Lipofectamine:	DNA	including	1:1,	1:1.22,	1:2,	1:2.33,	1:3,	1:3.33,	
1:4,	1.4:1,	2:1.	
	
c. 	AT84	cell	line	
AT84	cells	were	acquired	from	the	Paolini	group	in	Italy	and	are	a	spontaneously	
occurring	murine	head	and	neck	cancer.	The	cell	line	is	cultured	in	RPMI	1640	with	10%	fetal	
bovine	serum	or	synthetic	serum	Fetalgro.	The	cell	line	was	not	cultured	in	antibiotics	as	typical	
antibiotics,	such	as	penicillin/streptomycin,	used	in	cell	culture	may	interact	with	the	uptake	of	
G418	and	prevent	effective	selection.		Transfection	procedures	were	modified	from	the	
manufacturer	by	omitting	fetal	bovine	serum,	incubating	in	transfection	media	for	only	4-6	
hours,	and	using	a	ratio	of	Lipofectamine:	DNA	of	1:4.	
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2.4 Selection	of	stable	cell	line	
Cells	were	selected	using	G418	(Geneticin)	obtained	from	Gibco.	To	identify	the	correct	
dose	to	use	for	each	cell	line,	a	cell	toxicity	curve	was	generated.	Cells	were	plated	in	a	12	well	
plate	and	concentrations	ranging	from	0	μg/ml	to	1000	μg	/ml	were	tested	in	each	well.	
	
2.5 Imaging	
Fluorescent	imaging	was	performed	on	the	Olympus	IX83	microscope	and	images	were	
obtained	using	the	corresponding	CellSens	software.	To	assist	with	identifying	location	of	the	
plasmid	and	finding	the	correct	plane	of	cells,	cell	nuclei	were	dyed	10	minutes	prior	to	imaging	
with	Hoechst	stain.	The	Hoechst	stain	at	a	concentration	of	10	μg/ml	was	prepared	in	PBS	
immediately	prior	to	use.	Prior	to	application	of	the	dye,	cell	media	was	removed	and	the	cells	
were	washed	with	PBS.	Enough	Hoechst	10	μg/ml	solution	was	applied	to	cover	the	bottom	of	
the	well.	Upon	application,	cells	were	incubated	in	the	dark	at	room	temperature	for	5	minutes.	
The	solution	was	removed	and	the	cells	were	rinsed	twice	over	with	PBS	to	remove	excess	
unbound	stain.	Clear	cell	media	was	used	to	further	prevent	interference	with	fluorescence.	
Hoechst	stain	appears	blue.	The	presence	of	red	fluorescence	was	considered	an	
accurate	representation	of	the	location	of	the	calreticulin-containing	plasmid	when	reasonably	
located	near	the	blue-appearing	nucleus	bound	to	Hoechst	stain.	For	the	initial	confirmation	
studies	that	transfection	was	successful	prior	to	application	of	drug,	cells	were	split	onto	poly-L-
Lysine	coverslips	(Corning)	and	incubated	overnight.		
To	induce	translocation	of	the	calreticulin	protein	to	the	cell	membrane,	cells	were	
exposed	to	cisplatin	as	negative	control,	oxaliplatin,	and	modified	niclosamide.	Cell	toxicity	
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assays	were	run	to	determine	doses.	Cells	were	added	to	a	96	well	plate	at	a	concentration	of	
3000	cells	per	well	and	exposed	to	varying	concentrations	of	drug.	Cell	viability	was	assessed	
after	72	hours	of	treatment	with	the	three	drugs	using	resazurin	blue.		
Before	applying	the	drugs	to	transfected	cells,	cells	were	split	onto	collagen-coated	
chamber	slides.	Cells	were	plated	at	80%	confluency	when	drug	was	applied.	Oxaliplatin	was	
first	tested	at	concentrations	of	500	μM,	100	μM,	and	10	μM	incubated	with	cells	for	4	hours	
and	then	either	50	μl	or	100	μl	of	500	μM	or	100	μl	100	μM	for	12	and	24	hours.	Cisplatin	was	
tested	at	300	μM	incubated	with	cells	for	12	and	24	hours.	Either	20	μg	or	40	μg	of	Niclosamide	
was	applied	to	cells	for	12	and	24	hours.	
To	confirm	translocation	of	calreticulin	to	the	cell	membrane	after	exposure	to	these	
drugs,	the	cell-impermeable	HaloTag	AlexaFluor	488	was	used.	AlexaFluor	was	used	according	
to	the	manufacturer’s	instructions.	
	
Chapter	3:	Results	and	Discussion	
3.1 Transfection	
a. MDA	1986	
These	cells	were	chosen	for	their	similarity	to	cancers	involved	in	treatment	regimens	
with	known	ICD	inducers	as	well	as	for	their	accessibility	and	use	in	previous	projects	in	our	lab.	
Optimization	of	transfection	with	these	cells	proved	to	be	difficult	and	ultimately	resulted	in	no	
establishment	of	a	stable	cell	line.		
The	manufacturer	states	that	lipofectamine	can	successfully	be	used	in	media	containing	up	
to	10%	FBS.	However,	this	resulted	in	an	extremely	low—close	to	undetectable—transfection	
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efficiency	for	this	particular	cell	line,	even	with	high	amounts	of	lipofectamine	and	DNA.	In	the	
first	few	experiments,	the	only	changed	variable	was	the	amount	of	DNA	and	lipofectamine	
used.	For	example,	3,	5	or	7	microliters	of	lipofectamine	would	be	incubated	according	to	the	
manufacturer’s	directions	in	serum-free	DMEM,	
and	varying	concentrations	of	DNA—1	to	3	times	
the	concentration	of	lipofectamine—would	also	
be	incubated	in	serum-free	DMEM,	but	after	
mixing	and	incubating,	the	complexed	solution	
was	added	to	media	containing	serum	and	incubated	overnight.		After	several	tries	and	
increasing	the	possibility	of	lipofectamine	conditions	to	3,	5,	7,	10	and	12	microliters	each	with	
3,	5,	7,	10,	and	12	micrograms	of	DNA	respectively	and	still	seeing	an	extremely	low	
transfection	efficiency,	the	FBS	was	removed	from	the	process.		
	
	
Figure	13:	Selected	sample	images	of	
successfully	transfected	MDA	1986	cells	
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After	trying	the	same	conditions	again,	it	became	clear	that	FBS	was	the	problem,	as	
transfection	efficiency	increased.	While	the	manufacturer	says	that	it	is	possible	to	use	FBS,	it	is	
especially	essential	at	cell	lines	with	low	transfection	efficiency	to	leave	it	out.	Mechanistically,	
this	makes	sense.	Lipofectamine	and	other	transfection	agents	used	in	this	manner	are	often	
cationic	to	bind	to	anionic	DNA.	The	polyplex	is	then	neutral	and	can	cross	the	cell	membrane.	
However,	serum	albumin	is	also	negatively	charged,	and	it	may	competitively	bind	or	at	least	
interfere	with	the	binding	of	DNA	to	lipofectamine.	
After	removing	FBS,	the	transfection	efficiency	increased	to	5%	of	cells	in	the	well,	which	is	
extremely	low.	The	optimization	focus	changed	to	the	ratio	of	lipofectamine	to	DNA.	The	
manufacturer	states	that	in	their	cell	lines,	a	1:1	ratio	is	sufficient	to	see	transfection.	In	these	
cells,	the	1:1	or	lower	cells	showed	little	to	no	transfection,	whereas	the	1:2	and	larger	ratios	
showed	increasing	amounts	of	successful	transfection.		
Transfection	efficiency	may	increase	or	decrease	based	on	the	type	of	cells	and	their	
confluency.	Some	cell	lines	prefer	less	than	50%	confluency	to	improve	transfection,	but	the	
MDA	1986s	preferred	greater	than	50%	confluency	and	showed	improved	transfection	
efficiency	when	done	under	those	conditions.	After	removing	serum	from	the	transfection	
media	and	improving	the	ratio,	another	tested	condition	showed	that	60-70%	confluency	shows	
a	slightly	increased	number	of	transfected	cells.		
The	final	step	taken	to	improve	transfection	was	reducing	the	time	the	complexed	
transfection	solution	was	applied	to	cells.	As	indicated	by	the	manufacturer,	overnight	or	8-12	
hours	of	transfection	time	is	appropriate.	However,	it	is	suggested	that	some	cell	lines	are	
particularly	sensitive	to	lipofectamine	and	DNA,	and	it	may	be	cytotoxic.	The	final	step	to	
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optimization	with	these	cells	was	to	reduce	the	time	the	complex	was	applied	to	anywhere	
from	4-6	hours.	The	cells	looked	healthier	and	were	able	to	be	visualized	the	next	day,	but	it	
seemed	the	cells	were	a	dead	end	as	far	as	further	optimizing	the	transfection	protocol	as	less	
than	10%	of	all	cells	in	the	well	were	transfected	after	modifications	to	the	procedure.	
	
b. AT84	
AT84	cells	were	the	natural	next	step	after	the	MDA	1986	cell	line.	There	is	strong	evidence	
for	these	cells	as	a	pre-clinical	model	as	shown	in	work	done	by	Paolini91	et	al	and	they	are	a	
murine	cell	line	that	would	combine	well	with	the	next	step	of	processing	a	clinical	model	as	
they	can	be	injected	into	immunocompetent	mice.	Though	the	MDA	1986	cell	line	had	its	
failures,	the	lessons	learned	remained.	The	cell	line	was	transfected	at	minimum	70%	
confluency	with	ratios	1:2,	1:3,	and	1:4	of	Lipofectamine:	DNA	in	serum-free	media.	Un-
transfected	cells	were	challenged	side-by-side	with	serum	free	and	plus	serum	media.	The	
serum	free	cells	did	not	look	as	healthy	after	an	overnight	incubation	without	serum.	Rather	
than	plating	these	cells	in	serum-free	media	overnight,	as	was	done	with	the	MDA	1986	cells,	
the	wells	containing	these	cells	were	replaced	with	serum	free	media	just	prior	to	incubation.	
It	was	discovered	that	the	AT84	cells	preferred	a	ratio	of	1:4	Lipofectamine:	DNA	and	a	
shorter	incubation	time,	closer	to	4	hours	than	6	hours.	These	cells	were	more	amenable	to	
transfection,	and	while	efficiency	was	still	not	high,	red	fluorescence	close	to	the	blue	
fluorescence	of	the	Hoechst	stain	indicated	the	protein	was	being	expressed	at	10%.	This	is	still	
not	ideal	based	on	results	stated	by	the	manufacturer	as	well	as	by	the	protocol	recommended	
by	DNA	2.0,	but	enough	cells	had	the	plasmid	to	continue	through	with	work	to	test	drugs.	
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The	cells	expressing	the	plasmid	and	calreticulin	protein	did	not	image	as	well	as	non-
transfected	cells.	The	transfected	cells	were	
usually	isolated	and	were	not	striated	after	
overnight	plating,	unlike	their	non-
transfected	counterparts.	The	transfected	
cells	generally	did	not	look	as	healthy	and	
this	may	have	been	contributing	to	the	
problem	of	stable	cell	line	generation.		
	 	
3.2 Selection	
a. MDA	1986	
Low	transfection	efficiency	does	not	mean	the	cells	are	unusable;	however,	it	does	increase	
the	amount	of	time	it	takes	for	the	stable	cell	line	to	be	formed.	By	selecting	cells	using	the	
Figure	14:	Selected	initial	images	of	successfully	
transfected	AT84	cells	
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G418	resistance	conferred	by	the	plasmid	and	growing	up	those	cells	in	media	with	G418	for	4-
7	days,	100%	of	cells	in	the	flask	should	express	the	plasmid	and	therefore	the	protein.	A	
selection	curve	was	run	on	un-transfected	MDA	1986	cells.	After	5	days,	it	seemed	that	100%	of	
cells	incubated	with	300	μg/ml	of	G418	were	dead	and	it	was	chosen	as	the	optimal	selection	
concentration.	After	applying	300	μg/ml	G418	to	transfected	cells,	there	was	significant	cell	
death,	and	then	improvement	as	the	cells	selected	began	to	proliferate.	
However,	when	imaged	after	4	days	of	selection	with	300	μg/ml	G418,	less	than	1%	of	
MDA1986	cells	remained	transfected	as	confirmed	by	detection	of	the	red	fluorescent	protein.	
The	selected	cell	line	should	have	been	stable,	but	did	not	succeed	in	keeping	the	plasmid.	
When	replicating	the	selection	curve	results,	cells	at	lower	concentrations	began	dying	faster	
than	at	higher	concentrations	and	there	was	no	direct	curve.	It	is	likely	that	the	MDA	1986	cells	
have	some	level	of	intrinsic	resistance	to	G418.	This	cell	line	has	significantly	less	data	and	use	
in	published	papers	as	compared	to	many	other	cell	lines,	and	it	does	not	seem	that	others	
have	attempted	to	use	G418	on	these	cells	in	published	work.	The	decision	was	made	to	
discontinue	work	with	this	cell	line,	as	it	would	not	have	been	a	good	model	to	continue	using	
in	immunocompetent	mice	as	it	was	a	human	cell	line.		
	
b. AT84		
AT84	cells	had	been	used	previously	in	transfection	and	selected	by	Paolini	et	al	in	Italy	at	a	
concentration	of	400	μg/ml.	Cells	were	selected	with	G418	at	this	concentration	for	4	days	then	
split	onto	coverslips	for	imaging.	Again,	only	1-3%	of	cells	in	on	the	coverslip	maintained	the	
plasmid	and	protein	expression	as	measured	by	the	red	fluorescent	protein.	It	is	possible	that	
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the	cells	are	not	easily	amenable	to	this	type	of	transfection.	Plasmid	DNA	is	easily	removed	
from	the	cell,	whereas	retroviral	transfection	methods	make	that	more	difficult	by	editing	the	
host	genome.	A	stable	cell	line	was	unable	to	be	developed	through	this	method,	though	the	
transient	transfections	were	still	able	to	accurately	predict	if	a	drug	has	the	potential	to	induce	
immunogenic	cell	death.	The	pre-clinical	model	is	viable,	but	the	generation	of	a	stable	cell	line	
for	continuous,	rapid	testing	of	immunogenic	cell	death	is	not	possible	with	this	plasmid	
construct,	cell	line,	and	transfection	agent.		
3.3 Drug	testing	
a. Oxaliplatin	
Oxaliplatin	was	first	tested	at	10,	100,	and	500	μM	concentrations	incubated	with	the	
transiently	transfected	cell	line	for	4	hours.	According	to	Obied	et	al,	calreticulin	translocation	
and	exposure	could	occur	as	soon	as	one	hour	following	endoplasmic	reticulum	stress.	This	was	
not	true	for	this	cell	line	at	these	concentrations,	as	there	was	no	fluorescence	indicating	the	
presence	of	bound	HaloTag	AlexaFluor	to	surface-exposed	calreticulin.	These	experiments	using	
drug	and	AlexaFluor	were	done	in	chamber	slides,	which	are	wells	small	enough	to	contain	only	
7%	of	the	cells	split	from	a	6	well	plate.	After	incubation	with	oxaliplatin	for	only	four	hours,	
expression	of	protein	was	significantly	higher	than	seen	5	hours	previously	in	the	same	
transiently	transfected	cell	line	on	a	coverslip.	The	transfection	efficiency	was	near	15%,	an	
almost	5%	increase.		
It	is	extremely	unlikely	that	by	random	chance,	each	of	the	7	wells	of	transfected	cells	
on	the	chamber	slide	randomly	received	more	transfected	cells	than	cells	split	from	the	same	
line	onto	coverslips.	The	difference	must	be	exposure	to	oxaliplatin.	It	seems	that	oxaliplatin	or	
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some	other	form	of	endoplasmic	reticulum	is	necessary	for	selection	and	generation	of	a	stable	
cell	line,	as	the	protein	functions	in	these	conditions	and	is	less	likely	to	be	lost	from	the	cell.		If	
there	is	no	purpose	to	holding	onto	a	relatively	large	plasmid	construct	taking	up	valuable	space	
in	the	cell,	it	would	make	sense	for	the	cell	to	expel	it	during	replication.	However,	in	these	
conditions,	soon	after	transfection,	the	protein	is	utilized,	and	expression	is	increased.	These	
conditions	also	showed	the	first	double	transfection	and	expression	by	a	single	cell,	showing	
more	support	for	this	condition	as	a	requirement	for	selection.			
Figure	14:	Selected	sample	images	of	successfully	transfected	AT84	cells	after	exposure	to	oxaliplatin	
after	4	hours	at	varying	concentrations—500iNC	mM,	100	mM	and	10	mM		
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The	next	conditions	tested	were	100	μM	or	500	μM	for	12	and	24	hours.	Either	50	μl	of	
solution	or	100	μl	of	solution	was	applied	to	the	chamber	slides.	While	the	4-hour	incubation	
period	was	not	long	enough	to	allow	extracellular	protein	expression,	the	12	and	24-hour	
incubations	seemed	to	be	too	long.	The	amount	of	visible	and	fluorescent	calreticulin	was	
dramatically	lower	across	every	concentration,	but	there	were	red	cells.	A	few	cells	both	in	the	
12	and	24-hour	incubations	showed	the	classic	display	of	ICD	with	the	blue	Hoechst-stained	
nucleus,	red-orange	calreticulin,	and	green	AlexaFluor	bound	brightly	to	the	cell	membrane.	
While	this	is	a	low	number	of	cells	expressing	the	construct,	the	transient	transfection	does	
appropriately	display	immunogenic	cell	death	in	this	cell	line	with	oxaliplatin	as	the	positive	
control.	The	decreased	number	of	cells	in	each	slide	as	compared	to	the	4-hour	incubation	
could	be	attributed	to	a	poor	transfection,	but	also	may	be	due	to	the	rapid	response	of	
calreticulin.	It	is	possible	that	dosing	for	12	or	24	hours	causes	so	much	stress	and	cell	death	
that	the	calreticulin	has	already	responded	and	been	flushed	out	of	the	cell,	which	is	then	lost	
Figure	16:	Calreticulin	with	halotag	construct	binds	AlexaFluor.		
A. Microscopy	with	TRITC	and	DAPI	filters	showing	location	of	cells	and	
calreticulin	protein.		
B. Microscopy	with	FITC,	TRITC	and	DAPI	filters	
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in	changing	cell	media	with	AlexaFluor	staining.	More	supporting	evidence	for	this	is	the	quality	
of	cells	at	higher	doses	of	oxaliplatin	rapidly	declines	and	the	number	of	calreticulin-fluorescing	
cells	in	those	conditions	is	also	lower.		
	
	
	
	
	
	
	
	
Figure	17:	Calreticulin	exposed	on	the	surface	of	cells	after	treatment	with	oxaliplatin	binds	AlexaFluor.		
A. Fluorescence	of	Hoechst	stain,	RFP	from	Calreticulin	construct,	and	Alexa	Fluor	
B. Alexa	Fluor	florescence	alone	
C. RFP	and	Hoechst	stain	fluorescence	
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b. Niclosamide	
Though	an	old	drug,	niclosamide	has	been	investigated	recently	for	its	properties	in	
cancer	chemotherapy.	Though	there	is	nothing	in	the	literature	to	prove	that	it	induces	ICD,	we	
hypothesize	that	it	may.	
Niclosamide	should	undergo	a	full	
ICD	investigation,	including	the	
bona-fide	murine	vaccination	
study.	This	is	further	supported	
from	a	mechanistic	perspective,	
as	it	disrupts	electron	gradients	in	
the	mitochondria.	A	modified	
version	of	this	agent	was	
administered	to	cells	and	showed	
a	significant	effect	on	cell	
toxicity,	after	both	12	and	24-
hour	incubation	with	40	μg	
niclosamide.	In	addition	to	the	increased	cell	debris,	it	is	essential	to	point	out	that	in	conditions	
where	cells	underwent	incubation	with	niclosamide,	the	cells	maintained	expression	(albeit	low	
expression)	of	the	calreticulin	construct	as	illustrated	by	fluorescence.	When	cells	were	not	
exposed	to	agents	causing	endoplasmic	reticulum	stress,	cells	lost	the	ability	to	express	the	
construct.	In	the	conditions	where	cells	were	exposed	to	niclosamide	for	24	hours,	a	few	cells	
also	bound	the	AlexaFluor,	indicating	that	calreticulin	had	been	translocated	to	the	cell	surface.	
Figure	18:	AT84	cells	express	calreticulin	and	increased	amounts	of	
cell	debris	after	12	hours	of	incubation	with	20	μg	modified	
niclosamide.	
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While	these	results	alone	are	not	enough	to	definitivelysay	that	niclosamide	induces	
immunogenic	cell	death,	it	is	a	possibility	that	cannot	be	ignored.	The	solid	foundation	of	pre-
clinical	evidence	necessitates	further	study	with	this	agent	and	ICD.	
	
c. Cisplatin	
As	expected,	cells	incubated	with	cisplatin	did	not	show	fluorescence	with	the	
AlexaFluor	indicating	that	surface	exposure	of	calreticulin	(and	thereby	immunogenic	cell	
death)	was	occurring.	Cisplatin	served	as	the	negative	control	for	this	study.	Interestingly	
enough,	there	were	no	cells	in	the	four	wells	treated	with	cisplatin	after	either	12	or	24	hours	
of	incubation	expressing	the	expected	calreticulin	fluorescence.	Combined	with	earlier	clinical	
data	from	the	4-hour	oxaliplatin	incubation,	it	seems	that	the	inability	to	select	a	stable	cell	line	
could	require	not	just	culturing	with	G418,	but	also	low	levels	of	a	ER-stress-inducing	agent	as	
Figure	19:	Transfected	AT84	cells	translocate	calreticulin	to	the	cell	surface	when	exposed	to	niclosamide.	
A. Hoechst	and	Calreticulin	Fluorescence	
B. Hoechst,	Calreticulin,	and	AlexaFluor	Fluorescence	
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well.	An	important	note	is	that	the	cisplatin	is	clearly	working	on	these	cells	due	to	the	large	
amounts	of	cell	debris	and	stained	nucleic	acids,	it	simply	does	not	induce	immunogenic	cell	
death,	confer	stable	transfection	and	maintenance	of	the	calreticulin	plasmid,	or	bind	the	
AlexaFluor	construct.		
	
Chapter	4:	Conclusion	
4.1 The	Impact	of	Immunogenic	Cell	Death		
Harnessing	the	potential	of	immunogenic	cell	death	could	radically	change	the	way	cancer	is	
treated	in	the	modern	world.	By	fully	involving	the	immune	system	in	a	patient’s	anticancer	
regimen,	it	could	greatly	enhance	cytotoxic	therapy	and	improve	the	efficacy	of	newer	agents	
such	as	checkpoint	inhibitors.	Remission	rates	would	dramatically	increase	and	a	patient’s	
likelihood	of	developing	metastatic	disease	would	drop.	Involving	the	immune	system	
overcomes	one	of	the	requirements	of	cancer	development—evasion	of	the	immune	system.	
Figure	20:	Representative	images	for	transfected	AT84	cells	treated	with	cisplatin.	
A. Incubation	for	12	hours	with	50	μl	of	300	μM	cisplatin		
B. Visible	loose	nucleic	acids	after	incubation	of	100	μl	300	μM	cisplatin	for	12	hours.	
C. 50	μl	of	300	μM	cisplatin	incubated	for	24	hours.		
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By	stimulating	the	body’s	endogenous	response,	cancer	development	is	slowed	and	prevented	
in	the	future.	Identifying	which	chemotherapeutic	agents	that	create	this	response	and	also	
provide	a	potent	cytotoxic	effect	would	be	show	ideal	agents	for	use	in	various	cancers,	
especially	those	more	likely	to	metastasize.		
If	developing	and	modifying	new	cancer	chemotherapeutics	that	maintain	cytotoxicity	as	
well	as	causing	an	immune	response	is	too	costly,	it	could	also	be	possible	to	investigate	or	
modify	older	agents,	such	as	niclosamide,	not	traditionally	used	for	cancer	chemotherapy.	If	
these	agents	successfully	create	an	immune	response	via	immunogenic	cell	death,	they	could	
be	added	in	to	current	regimens.	Induction	of	immunogenic	cell	death	is	one	new	mechanism	
of	action	that	should	be	considered	when	creating	regimens	for	cancer	chemotherapy.	
Regimens	containing	mechanisms	of	actions	were	originally	designed	to	prevent	resistance,	but	
in	this	case,	multiple	mechanisms	of	action	could	also	improve	killing	strategies.	Causing	ICD	
may	actually	be	more	beneficial	when	done	by	a	nontraditional	cancer	chemotherapeutic,	as	
those	agents	tend	to	have	an	improved	side	effect	profile	and	do	not	typically	cause	bone	
marrow	suppression	resulting	in	an	impaired	immune	system.		
Rapid,	low-cost	detection	of	ICD	remains	a	problem	that	slows	development	and	further	
characterization	of	this	response	as	well	as	the	agents	that	potentially	cause	it.	If	ICD	could	be	
detected	without	using	animal	models,	the	current	gold	standard,	and	could	take	less	than	2-4	
weeks,	it	would	be	more	feasible	for	all	agents	to	be	tested	for	this	response.	Additionally,	it	
would	be	realistic	to	re-test	agents	that	may	have	been	shown	not	to	cause	it	in	the	past.	It	is	
possible	that	some	of	these	agents,	particularly	the	ones	that	cause	immunosuppression,	must	
be	used	at	lower	doses	to	accurately	assess	if	they	cause	ICD.	In	this	work,	a	rapid	and	relatively	
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low-cost	method	of	detection	using	transient	transfection	of	murine	cells	was	identified,	which	
could	be	transferred	to	immune-competent	murine	models	to	detect	ICD	via	the	gold	standard	
method.		
	
4.2 Feasibility	of	a	Pre-Clinical	Model	
This	work,	while	identifying	cell	lines	as	a	potential	pre-clinical	model	for	immunogenic	cell	
death	using	fluorescent	stains	and	tags,	has	much	to	be	improved	on.	Lipofectamine	is	not	a	
realistic	transfection	agent	for	generation	of	a	stably	transfected	cell	line	with	this	line	and	
plasmid	construct.	However,	the	transient	transfections	were	able	to	accurately	predict	
generation	of	immunogenic	cell	death	as	shown	by	the	positive	and	negative	controls,	
oxaliplatin	and	cisplatin.	Use	of	the	transient	transfection	model	should	not	be	entirely	
dismissed	as	it	is	relatively	cheap	and	can	be	completed	in	four	days.	These	pre-clinical	models	
should	not	be	used	alone	to	definitively	say	whether	an	agent	does	or	does	not	induce	
immunogenic	cell	death.	Rather,	these	models	could	be	used	as	more	high-throughput	method	
to	determine	the	potential	and	likelihood	of	an	agent	to	induce	immunogenic	cell	death.	It	is	
considerably	easier	to	test	wide	varieties	of	concentrations,	exposure	times,	and	drug	classes	
with	this	model	than	with	expensive	murine	models,	and	the	utility	should	not	be	entirely	
dismissed.	
	
4.3	Future	Directions	
a. Lentiviral	transfection	
Generation	of	a	stable	cell	line	using	another,	slightly	more	expensive	cell	line	will	be	
done	using	lentiviral	transfection	methods.	This	will	likely	be	superior	to	the	lipofectamine	and	
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plasmid	method	as	the	lentivirus	is	significantly	harder	to	remove	from	the	cell	and	cannot	
simply	be	shuffled	out	via	efflux.	Lentiviral	transfections	modify	the	DNA	within	the	nucleus	and	
zip	the	plasmid	construct	into	the	host	DNA,	making	it	almost	impossible	for	the	host	cell	to	
remove.	There	are	optimization	methods	to	accompany	this	form	of	transfection	as	well,	but	
after	the	transfection	is	found	to	be	successful,	generation	and	maintenance	of	the	stable	cell	
line	is	considerably	more	likely.	Testing	of	agents	could	be	done	in	two	days—half	the	time—
and	as	the	transfection	efficiency	is	higher	than	the	transient	lipofectamine	transfections,	could	
provide	a	stronger	suggestion	as	to	the	potential	of	inducing	immunogenic	cell	death.	In	the	
transient	transfections,	there	is	a	higher	chance	for	error	because	there	are	fewer	cells	even	
available	for	imaging.	
	
b. Murine	models	
The	murine	model	remains	the	gold	standard	to	prove	a	drug	causes	ICD.	After	
generation	of	a	stable	murine	cell	line	that	can	detect	ICD	potential,	continuity	can	be	
maintained	by	using	the	same	transfected	cell	line	to	prove	the	agent	causes	ICD	in	mice.	The	
continuity	from	cell	line	to	cell	line	increases	the	likelihood	that	an	agent	will	be	able	to	cause	
ICD	at	doses	already	tested	in	murine	cells.	It	is	a	low-cost	step	that	prevents	optimization	at	
higher	cost	models,	and	will	be	essential	as	the	final	step	of	the	assay.	Though	the	murine	
model	does	have	its	own	problems	as	far	as	generalizability	to	human	cell	lines,	addition	of	this	
step	will	make	it	easier	to	test	from	compound	to	compound,	mouse	to	mouse.		The	
niclosamide	analog	should	be	further	investigated	using	this	gold-standard	method	based	on	
the	strong	evidence	in	this	study.		
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c. Testing	of	a	modified	Platinum	compound	
Collaborators	in	our	lab	have	been	working	on	a	modified	platinum	compound	that	should	
be	tested	for	its	capability	to	induce	immunogenic	cell	death.	The	compound	was	not	available	
for	testing	at	the	time	of	this	work,	but	will	be	tested	with	the	new	transfection	method	to	
assess	ICD.		
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